Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Erasca, Inc. (ERAS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
7.61+0.27 (+3.68%)
At close: 04:00PM EST
7.61 0.00 (0.00%)
After hours: 04:02PM EST
Advertisement
Full screen
Loading interactive chart...
  • GlobeNewswire

    Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pierre Fabre to Evaluate ERAS-007 and Encorafenib Combination

    ERAS-007, a potential best-in-class ERK1/2 inhibitor, is being evaluated in combination with encorafenib and cetuximab in BRAF V600E-mutant metastatic colorectal cancer Erasca previously signed CTCSAs with Pfizer and Eli Lilly to evaluate encorafenib and cetuximab in combination with ERAS-007 SAN DIEGO, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patient

  • GlobeNewswire

    Erasca to Present at Upcoming Investor Conferences

    SAN DIEGO, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that company management will present at the following investor conferences: 5th Annual Evercore ISI HealthCONx Conference (November 29 – December 1, Virtual) Format: Fireside Chat Date and Time: Tuesday, November 29, 8:50 – 9:10 AM EST We

  • Zacks

    Wall Street Analysts Predict a 126% Upside in Erasca, Inc. (ERAS): Here's What You Should Know

    The average of price targets set by Wall Street analysts indicates a potential upside of 125.9% in Erasca, Inc. (ERAS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Advertisement
Advertisement